Wockhardt Limited has informed the Exchange about Investor Presentation

Wockhardt filed an updated investor presentation highlighting strong FY25 results with total income of INR 3,033 Cr (5% growth) and EBITDA of INR 418 Cr, a sharp 67% jump from INR 251 Cr in FY24. EBITDA margins expanded from 9% to 14%, and net debt-equity ratio improved dramatically to 0.01 after a INR 397 Cr debt reduction and INR 1,000 Cr raised through a QIP. The company showcased progress on its novel antibiotics pipeline, including Zaynich (WCK 5222) where global Phase III cUTI study was completed with 20% superiority over Meropenem, and Miqnaf (Nafithromycin), the first new macrolide antibiotic in 30 years, which has been launched in India. The company outlined a TAM of ~US$ 9 billion for Zaynich across US, Europe and India, INR 10,800 Cr for Miqnaf in India, and targets 20-25% growth in its diabetes biosimilars business which is doubling capacity over 3 years.